Powered by proprietary single-molecule next-generation sequencing (smNGS) technology, Northstar Select sets a new standard in sensitivity for non-invasive, blood-based comprehensive genomic profiling of advanced solid tumor cancers by uncovering over 50% more clinically actionable alterations compared to other tests

MENLO PARK, Calif. , Aug. 26, 2025 /PRNewswire/ -- BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling 1 . The study validates Northstar Selec t , BillionToOne's highly sensitive comprehensive genomic profiling (CGP) liquid biopsy a

See Full Page